Hematopoiesis News Volume 12.12 | Apr 6 2021

    0
    17







    2021-04-06 | Hema 12.12


    Hematopoiesis News by STEMCELL Technologies
    Vol. 12.12 – 6 April, 2021
    TOP STORY

    Platelet Autophagic Machinery Involved in Thrombosis through a Novel Linkage of AMPK-MTOR to Sphingolipid Metabolism

    The authors revealed that LC3-II formation and SQSTM1/p62 degradation were noted in H2O2-activated human platelets, which could be blocked by 3-methyladenine and bafilomycin A1, indicating that platelet activation may cause platelet autophagy.
    [Autophagy]

    Full Article
    The StemSpanâ„¢ T Cell Generation Kit is designed to promote differentiation of HSPCs into T cells in stroma- and serum-free culture conditions.
    PUBLICATIONSRanked by the impact factor of the journal

    A Single-Cell Resolution Developmental Atlas of Hematopoietic Stem and Progenitor Cell Expansion in Zebrafish

    Using single-cell RNA-sequencing, researchers deciphered a dynamic atlas covering 28,777 cells and nine major cell types of zebrafish caudal hematopoietic tissue.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Full Article

    Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia

    Scientists found that leukemic stem cells in chronic myelomonocytic leukemia resided in a CD34+/CD38− fraction of the malignant clone.
    [Leukemia]

    Abstract

    Protein S-Nitrosylation Regulates Proteostasis and Viability of Hematopoietic Stem Cell during Regeneration

    Investigators found increased nitric oxide during HSC regeneration with an accumulation of protein aggregation.
    [Cell Reports]

    Full Article

    Phase II-Like Murine Trial Identifies Synergy between Dexamethasone and Dasatinib in T-Cell Acute Lymphoblastic Leukemia

    Researchers performed an shRNA screen in vitro and in vivo in T-cell acute lymphoblastic leukemia cell lines and patient derived xenograft samples to identify vulnerabilities in the pTCR/TCR pathway and identified a critical role for the kinase LCK in cell proliferation.
    [Haematologica]

    Full ArticleGraphical Abstract

    Combining Ibrutinib and Checkpoint Blockade Improves CD8+ T-Cell Function and Control of Chronic Lymphocytic Leukemia in Em-TCL1 Mice

    By using the Eµ-TCL1 adoptive transfer mouse model of chronic lymphocytic leukemia, scientists observed that ibrutinib effectively controled leukemia development, but also resulted in significantly lower numbers of CD8+ effector T-cells, with lower expression of activation markers, as well as impaired proliferation and effector function.
    [Haematologica]

    Full Article

    Attrition of X Chromosome Inactivation in Aged Hematopoietic Stem Cells

    Researchers demonstrated that LaminA/C defined a distinct repressive nuclear compartment for X chromosome inactivation (XCI) in young HSCs, and its reduction in aged HSCs correlated with an impairment in the overall control of XCI.
    [Stem Cell Reports]

    AbstractFull ArticleGraphical Abstract

    Outcome of Haploidentical versus Matched Sibling Donors in Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Lymphoblastic Leukemia: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

    Investigators retrospectively analyzed adult patients with acute lymphoblastic leukemia who underwent their first allogeneic stem cell transplantation in first or second complete remission between 2012 and 2018, either from a T cell replete Haplo or matched sibling donor donor.
    [Journal of Hematology & Oncology]

    Full Article

    Azacitidine for Relapse of Acute Myeloid Leukemia or Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation, Multicenter PALG Analysis

    The authors conducted retrospective multicenter analysis of patients diagnosed with acute myeloid leukemia or myelodysplastic syndromes who had hematological relapse after allogeneic hematopoietic stem cell transplantation and were treated with azacitidine for this indication.
    [European Journal of Haematology]

    Abstract
    Explore scientific events this April with the Science Events Calendar.
    REVIEWS

    Diffuse Large B-Cell Lymphoma: New Targets and Novel Therapies

    Three CAR-T cell products are currently approved by the FDA, with others in clinical trials. Additional agents in development include bispecific antibodies and antibody drug conjugates.
    [Blood Cancer Journal]

    Full Article

    Rebuilding the Hematopoietic Stem Cell Niche: Recent Developments and Future Prospects

    Investigators highlight two areas in the field of HSC research, which just started to unlock the possibilities provided by novel biomaterials, in vitro blood production and studying the pathophysiology of the niche in vitro.
    [Acta Biomaterialia]

    Full Article
    INDUSTRY AND POLICY NEWS

    Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage II of Phase II Clinical Trial in Acute Myeloid Leukemia

    Bio-Path Holdings, Inc. announced the successful completion of the safety run-in of the Stage II of the Phase II clinical study of prexigebersen, a liposomal Grb2 antisense, for the treatment of acute myeloid leukemia (AML), in combination with frontline therapies, decitabine and venetoclax, in AML patients.
    [Bio-Path Holdings, Inc.]

    Press Release

    Kite Submits Supplemental Biologics License Application to US Food and Drug Administration for Tecartus® in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

    Kite announced that it has submitted a supplemental Biologics License Application to FDA for Tecartus® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
    [Kite (BusinessWire, Inc.)]

    Press Release
    FEATURED EVENT

    Cambridge Cancer Epigenetics Club: Ruud Delwel

    Jul 2, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Journal Editor – Blood Cancer Discovery and Cancer Immunology

    American Association for Cancer Research – Boston, Massachusetts, United States

    Postdoctoral Fellow – Myeloma Tumor Microenvironment

    Moores Cancer Center – La Jolla, California, United States

    Assistant Professor – Hematology

    University of Washington – Seattle, Washington, United States

    Postdoctoral Fellow – Myeloma Tumor Microenvironment

    Moores Cancer Center – La Jolla, California, United States

    Medicinal Chemist – Muscle-Wasting, Neurodegeneration, and Oncology

    Almac – Belfast, Ireland

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter